Making a list of penny stocks to buy? Check these 7 out for some inspiration
The post 7 Top Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
As we turn the corner to July, penny stocks are heating up. This is marked by both higher than average volume, and relatively large gains seen across the board. While some investors were worried after the past two months or so of relatively sideways trading, the past week has been more or so comforting. Considering this, there are hundreds of penny stocks to watch right now. But, understanding how to find the most value can be a challenge.
So, doing as much research as possible and understanding what moves are being made, can help to make you a profitable trader. Right now, the impact of Reddit and Twitter is massive on small-caps. That means that investors need to stay up to date on all the latest events in the stock market and on social media. With all of this in mind, are these seven penny stocks worth watching next month?
Genius Brands International Inc. is an entertainment penny stock that we have frequently mentioned due to its consistent advancements. This company is focused on content and brand management as well as the creation and licensing of content. Its content is generally aimed at the youth market such as the ages of 2-12. It has many active series that continue to promote its viewership every week.
On June 8th, the company announced that it will join the Russell 3000 Index after the conclusion of the 2021 Russell indexes annual reconstitution. This will be active when the market opens on June 28th, 2021. One month ago, GNUS stock was around $1.55 per share and it has now reached nearly $2 per share as of June 23rd.
“We’re pleased to be included in the Russell 3000 and Russell 2000 Indexes, as we believe this reflects the dramatic growth we have experienced over the past year.
In particular, our recently launched tentpole brand, Stan Lee’s Superhero Kindergarten, starring Arnold Schwarzenegger, has now surpassed 28 million views, averaging now over 4 million views per episode, making this one of the most highly viewed new cartoon launches in history.”
The CEO of Genius Brands
So considering this, will GNUS make your penny stock watchlist after noting the above information?
Ayro Inc. (NASDAQ: AYRO)
The market for electric vehicle stocks like Ayro Inc. has grown substantially in the last year and a half. Ayro is a company that designs and manufactures light-duty emissions-free electric vehicles. These vehicles are used for community transport, local delivery, closed campus mobility, government use, among many more uses.
It’s AYRO 311 3-wheeled vehicle is for professional and personal use. Additionally, its Club Car 411 product is for low-speed logistics and cargo services on campuses. While many investors focus on EV vehicles for consumers, few consider the massive market for transport and industrial use. This is where Ayro comes in.
On June 8th the newest big update came from Ayro Inc. It announced that it had received $2 million in a purchase order for its new Club Car Current EV following its launch. This vehicle will be launched in 2022, and in the meantime, could be a breakthrough for the EV industry.
“Club Car has been a strong partner for getting our light-duty, low-speed EVs to customers that need them, and this purchase order is a great example of our successful collaboration.
The Club Car Current navigates campuses and narrow urban streets seamlessly while also carrying significant loads for meeting last-mile distribution challenges—this is something most other EV’s are not designed to handle.”
The CEO of AYRO Rod Keller
On June 23rd, AYRO stock price increased by about 5%. Whether this makes AYRO stock worth watching is up to you.
Universal Power Industry Corporation (OTC: UPIN)
Next up on this penny stock watchlist is Universal Power Industry Corporation. This company develops certified offshore programmers’ databases. Its database is currently used to locate and refer qualified programmers to respective industries. Additionally, it provides programming services to offshore vessels, which has become a sizable industry in the past few years.
There is no current company-specific news that is causing the price of UPIN stock to increase in the market right now. What we do know is that the growth of this penny stock is undeniable. At the start of 2021, UPIN stock was at $0.04 per share on average. Now as of June 23rd, UPIN stock price has reached past $0.25 per share on average. This becomes more impressive when you consider that a lot of this momentum started just one month ago.
One thing to keep in mind is that UPIN is an OTC listed stock and a highly volatile one at that. So, if you’re comfortable with large price fluctuations, it could be worth watching. But if not, it may be best to avoid UPIN stock. On June 23rd, UPIN stock opened at $0.2250 per share and closed at $0.2582 per share. This 9.29% increase in stock price is likely to continue increasing the popularity of UPIN moving forward. While it is highly volatile, it could be worth keeping an eye on.
Ebang International Holdings Inc. (NASDAQ: EBON)
Ebang International Holdings Inc. is a tech penny stock that researches, designs, and develops app-specific integrated circuit chips. The company also manufactures Bitcoin mining machines in China, the U.S., and Hong Kong. As you may have heard, the crypto market is seeing a great deal of volatility right now.
Following Bitcoin dipping below $30,000 for the first time in months, we are now seeing many leading cryptocurrencies push up in value. While some newcomers to crypto may be scared about the recent Bitcoin price action, those who have invested for a long time know that this is par for the course.
Ebang also provides mining machine hosting services that give customers the ability to operate machines remotely as well as perform basic maintenance operations. Additionally, it sells fiber optical telecommunication products, and much more. Given that the circuit chip market is in a vast supply shortage with major demand, many investors are focused on companies like EBON right now.
Following a day of negatives on June 22nd when EBON stock took a large dip, things are turning around for the tech penny stock. EBON stock opened high on June 23rd at $3.20 per share and eventually went down to $3.10 per share by the end of the day. Just one month ago, EBON stock was at about $2.50 per share on average. This Bitcoin mining machine maker has grown vastly in the last month and with the bulls coming into crypto right now, it could be worth keeping an eye on.
Evofem Biosciences Inc. (NASDAQ: EVFM)
Evofem Biosciences Inc. is a biotech penny stock developing and commercializing products for unmet needs in women’s sexual and reproductive health. Its current commercial product is Phexxi, which is a contraceptive gel. It also has anti-STD developments in the works, such as EVO100 which is an antimicrobial gel for preventing urogenital transmission of Chlamydia.
This company’s latest updates surround its presentations at several industry-leading conferences. It recently presented at the Jefferies Virtual Healthcare Conference 2021 and the LD Micro Invitational XI. Additionally, Evofem closed a $50 million public offering in mid-May that should give it ample funding into the near future and beyond.
The net proceeds from the public offering will be in use for the continuation of full commercialization activities related to Phexxi. Additionally, this funding will go toward advertising, continuing clinical trials, and more. EVFM stock was at $0.81 per share one month ago. Now on June 23rd, EVFM stock is at $1.19 per share on average. With this in mind, is EVFM stock worth keeping an eye on or not?
Marin Software Inc. (NASDAQ: MRIN)
MRIN stock is one of the largest gainers of the day, pushing up by as much as 54% by midday. While many large gains like this occur without news, MRIN made headlines today surrounding a new integration with its flagship MarinOne platform. Before we get into this, let’s talk about what Marin Software does. Marin Software is a company that offers advertising services for paid marketing programs. It integrates a SaaS advertising manager for paid search, social, and eCommerce purposes worldwide.
Today, it announced the integration of Instacart Ads to its MarinOne platform. Instacart is widely regarded as being the largest online grocery platform in North America and delivers from over 55,000 stores across the U.S. and Canada.
“As the leading online grocery platform in North America, Instacart is a must-have part of digital marketing strategies. We are delighted to give advertisers on Instacart the power of MarinOne to maximize return on their investment.”
Chris Lien, CEO of Marin
Considering this big news, will MRIN be on your penny stocks watchlist moving forward?
Senseonics Holdings Inc. (NYSE: SENS)
SENS stock is another penny stock that we’ve covered plenty of times in the past few months. For those unfamiliar, Senseonics is a producer of diabetes-related products such as insulin monitors and more.
While this is a growing market and is a valuable part of SENS’s business, many believe that its recent price movements are due to its status as a meme stock. This is a category of stocks that rise and fall based on social media sentiment. When a stock is highly discussed on Reddit or Twitter, for example, many traders will jump on to try and get a piece of the action.
This results in the underlying stock trending heavily. In the past month, shares of SENS have shot up by over 80% and in the past six months by over 298%. This is a substantial gain and is again, reflective of both SENS products and its status as a trending penny stock. While this does make it more or less volatile, it could make it a penny stock to watch. With that in mind, what do you think? Is it worth keeping an eye on or not?
Which Penny Stocks Are You Watching Right Now?
Finding the best penny stocks to watch is all about understanding what makes them move. Right now this includes social media, the pandemic, cryptocurrency, and more.
[Read More] Best Penny Stocks To Buy Now? 7 To Watch This Week
Because there are so many factors to consider, it can at times seem difficult to keep up. Regardless, staying up to date with the news and all the latest market events will help to put you in the loop. With this in mind, which penny stocks are you watching right now?
It was Jan. 11, 2024 when software giant Microsoft (MSFT) briefly passed Apple (AAPL) as the most valuable company in the world.
Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion.
It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion.
"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.
The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.
Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue.
Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.
Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.
“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.
A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.
Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.
Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.
The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.
Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.
Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.
"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads.
"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.
Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify (SPOT) and other music streaming rivals via restrictions on the App Store.
The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.
Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com.
The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.
BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market.
Analyst says Apple selloff 'overdone'
Concurrently, prices for previous models are typically reduced by about $100 with each new release.
This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.
Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.
This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China.
BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.
The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.
On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”
The firm said that investors' growing preference for AI-focused stocks like Nvidia (NVDA) has led to a reallocation of funds away from Apple.
In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.
And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.
“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.
Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.
Credit: IVI
There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.
The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.
There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.
“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”
In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.
There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.
Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.
Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”
As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study
We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.
Maybe it will never matter. Maybe MMT is real. Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.
I have no idea. Only time will tell. But it’s going to be fascinating to watch it play out.
He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."
According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.
The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...
... and spending which is about 50% higher compared to where it was in 2020.
The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.
And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.
But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).
... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.
We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...
.. which lays out the proposed Biden budget as follows:
The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.
Without them the deficit will grow $19 trillion.
That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.
No family budget or business could exist with this kind of math.
Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
